Chronic Myeloid Leukemia
Enliven Therapeutics Inc. is active in hematologic malignancy research, with a focus on chronic myeloid leukemia and targeted treatment development.
- Chronic myeloid leukemia
- Targeted oncology
- Leukemia therapeutics
Its clinical portfolio includes work in disease settings driven by oncogenic signaling abnormalities and treatment-resistant cancer biology.
HER2-Driven Solid Tumors
The sponsor investigates HER2-positive, HER2-amplified, and HER2-mutant solid tumors, including advanced cancers with distinct HER2 alterations.
- HER2-positive solid tumors
- HER2-amplified cancer
- HER2-mutant tumors
This includes broad interest across solid tumor types where HER2 biology is a central therapeutic target.
Non-Small Cell Lung Cancer
Enliven Therapeutics Inc. supports research in non-small cell lung cancer, particularly tumors with HER2 genetic alterations and advanced disease features.
- Non-small cell lung cancer
- HER2-mutant lung cancer
- Advanced thoracic oncology
Its activity in this area reflects interest in molecularly defined lung cancer populations.
Breast and Colorectal Cancer
The sponsor is involved in HER2-positive breast cancer and HER2-positive colorectal cancer, with attention to advanced and metastatic disease.
- HER2-positive breast cancer
- Metastatic breast cancer
- HER2-positive colorectal cancer
These programs place emphasis on tumor types where HER2-directed therapy remains clinically relevant.
